Long-term treatment with probiotics in primary care patients with irritable bowel syndrome – a randomised, double-blind, placebo controlled trial
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
OBJECTIVE. Meta-analyses have indicated effect of probiotics on irritable bowel syndrome (IBS). However, few long-term trials have been conducted and uncertainty remains as to effectiveness and long-term effect in a primary care setting. We aimed to investigate the effect of probiotics compared with placebo in the management of IBS in primary care during a 6-month treatment period and with a 6-month follow-up. MATERIAL AND METHODS. We randomized IBS patients fulfilling Rome III criteria to receive two capsules twice daily either containing placebo or a probiotic mixture of Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 and Bifidobacterium Bb12 in an amount of 1.3 × 10(10) CFU per capsule. Primary endpoint was proportion of responders defined as patients reporting adequate relief (AR) at least 50% of the time in the 6-month treatment period. Secondary outcomes were proportions of patients reporting AR at different time points, and change in gastrointestinal symptoms and health-related quality of life (HrQOL) from baseline to 6 and 12 months. RESULTS. A total of 131 patients were included in this study. The proportion of responders in the treatment period was 52% (35/67) in the probiotic group versus 41% (26/64) in the placebo group, p = 0.18. Overall we found no difference between the groups in change in gastrointestinal symptoms after treatment. Patients improved in HrQOL, but with no statistically significant difference between the groups. CONCLUSION. During a 6-month treatment period, we were not able to detect a positive effect of probiotic when compared with placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis
Lovell, R. M., & Ford, A. C. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.029 · Cited by 2,155
Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002 · cited 1×
“and 3) the fecal microbiota has proved to be significantly altered in IBS patients compared to healthy controls [7,8].”
BackgroundIntestinal microbiota in functional bowel disorders: a Rome foundation report
Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M. R., Spiller, R. C., Vanner, S., Verdu, E. F., Whorwell, P. J., & Zoetendal, E. G. (2013) · Gut · doi:10.1136/gutjnl-2012-302167 · Cited by 939 · cited 1×
“The current working hypothesis is that abnormal microbiota activate mucosal innate immune responses, thereby increasing epithelial permeability and activating nociceptive sensory pathways and dysregulating the enteric nervous system [2].”
BackgroundThe impact of irritable bowel syndrome on health-related quality of life
Gralnek, I. M., Hays, R. D., Kilbourne, A., Naliboff, B., & Mayer, E. A. (2000) · Gastroenterology · doi:10.1053/gast.2000.16484 · Cited by 781 · cited 1×
“IBS patients are known to have impaired healthrelated quality of life [28].”
BackgroundPatrick, D. L., Drossman, D. A., Frederick, I. O., Dicesare, J., & Puder, K. L. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018831127942 · Cited by 761 · cited 2×
“47 (37) 25 (38) 22 (35) Health-related quality of life SF-36 PCS, mean, (SD) 49.00 (7.51) 48.27(7.38) 49.63 (7.60) MCS, mean (SD) 48.26 (10.44) 49.10(9.99) 47.43(10.90) IBS-QOL, total score (SD) 73.33 (17.83) 73.23 (17.21) 73.43 (18.61) Psychological co morbidity HADS Anxiety score 7.10 (3.75) 6.81 (3.43) 7.42 (4.07)…”
MethodInfluentialThe efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review
Moayyedi, P., Ford, A. C., Talley, N. J., Cremonini, F., Foxx-Orenstein, A. E., Brandt, L. J., & Quigley, E. M. M. (2010) · Gut · doi:10.1136/gut.2008.167270 · Cited by 728 · cited 5×
“Clinical evidence for this is supported by the fact that: 1) IBS symptoms can develop in predisposed individuals following an enteric infection [3], 2) treatments targeting the microbiota such as antibiotics [4], probiotics [5] and prebiotics [6] have been suggested to be effective”
BackgroundResultInfluentialMalinen, E., Rinttila, T., Kajander, K., Matto, J., Kassinen, A., Krogius, L., Saarela, M., Korpela, R., & Palva, A. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.40312.x · Cited by 699 · cited 1×
“and 3) the fecal microbiota has proved to be significantly altered in IBS patients compared to healthy controls [7,8].”
BackgroundSILK, D. B. A., DAVIS, A., VULEVIC, J., TZORTZIS, G., & GIBSON, G. R. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03911.x · Cited by 551
THABANE, M., KOTTACHCHI, D. T., & MARSHALL, J. K. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03399.x · Cited by 466
Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire
Drossman, D. A., Patrick, D. L., Whitehead, W. E., Toner, B. B., Diamant, N. E., Hu, Y., Jia, H., & Bangdiwala, S. I. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01941.x · Cited by 424 · cited 2×
“47 (37) 25 (38) 22 (35) Health-related quality of life SF-36 PCS, mean, (SD) 49.00 (7.51) 48.27(7.38) 49.63 (7.60) MCS, mean (SD) 48.26 (10.44) 49.10(9.99) 47.43(10.90) IBS-QOL, total score (SD) 73.33 (17.83) 73.23 (17.21) 73.43 (18.61) Psychological co morbidity HADS Anxiety score 7.10 (3.75) 6.81 (3.43) 7.42 (4.07)…”
MethodInfluential
Research works printed but not linked: 10
- 10.1007/s11894-012-0284-2 · DOI
- 10.1016/j.cgh.2012.12.038 · DOI
- 10.1111/j.1365-2036.2010.04239.x · DOI · Paper page
- 10.1038/ajg.2013.15 · DOI · Paper page
- 10.1053/j.gastro.2009.08.047 · DOI · Paper page
- 10.1111/j.1572-0241.2003.07158.x · DOI · Paper page
- 10.1016/j.cgh.2007.03.004 · DOI
- 10.1111/j.1572-0241.2006.00535.x · DOI · Paper page
- 10.1038/ajg.2009.13 · DOI · Paper page
- 10.1017/S109285290001436X · DOI · Paper page
Cited by
Ford, A. C., Quigley, E. M. M., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Moayyedi, P. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.202 · Cited by 747
Ford, A. C., Moayyedi, P., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Quigley, E. M. M. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.187 · Cited by 645
Ford, A. C., Harris, L. A., Lacy, B. E., Quigley, E. M. M., & Moayyedi, P. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15001 · Cited by 619
American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome
Ford, A. C., Moayyedi, P., Chey, W. D., Harris, L. A., Lacy, B. E., Saito, Y. A., & Quigley, E. M. M. (2018) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0084-x · Cited by 388
McKenzie, Y. A., Bowyer, R. K., Leach, H., Gulia, P., Horobin, J., O'Sullivan, N. A., Pettitt, C., Reeves, L. B., Seamark, L., Williams, M., et al. (2016) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.12385 · Cited by 353
Metadata
- Authors
- Begtrup, L. M., de Muckadell, O. B. S., Kjeldsen, J., Christensen, R. D., & Jarbøl, D. E.
- Venue
- Scandinavian Journal of Gastroenterology
- Publisher
- Informa UK Limited
- Published
- 2013-08-19
- Volume
- 48
- Issue
- 10
- Pages
- 1127-1135
- ISSN
- 0036-5521 (ISSN-L)
- 1502-7708
- OpenAlex
- W2046984987
- Cited by
- 84
- References
- 18
- FWCI
- 5.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term treatment with probiotics in primary care patients with irritable bowel syndrome – a randomised, double-blind, placebo controlled trial. https://app.cochat.ai/papers/10.3109/00365521.2013.825314
- The paper
- Begtrup, L. M., de Muckadell, O. B. S., Kjeldsen, J., Christensen, R. D., & Jarbøl, D. E. (2013). Long-term treatment with probiotics in primary care patients with irritable bowel syndrome – a randomised, double-blind, placebo controlled trial. Scandinavian Journal of Gastroenterology. https://doi.org/10.3109/00365521.2013.825314
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.